NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 661-665

  Liu, H Eugene ^a   Hsiao, Pei Yu ^a   Lee, Ching Chen ^b   Lee, Jen Ai ^a   Chen, Hsiang Yin ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Shin Kong Wu Ho Su Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; ASTROCYTOMA; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; GLIOBLASTOMA; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; BRAIN TUMOR; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GENETIC POLYMORPHISM; GENETICS; RISK FACTOR; TAIWAN;

ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; TAIWAN;

EID: 41549146564     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2647     Document Type: Article

References (25)

1. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633-8.
2. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2005;25:1649-58.
3. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
4. Jaskula-Sztul R, Soko?owski W, Gajecka M, Szyfter K. Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. J Appl Genet 2001;42:223-31.
5. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006;7:58.
6. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996;56:3961-6.
7. Chiou HL, Wu MF, Chien WP, et al. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 2005;223:93-101.
8. Martinez C, Agundez J, Olivera M, Martin R, Ladero JM, Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995;5:207-14.
9. Peters ES, Kelsey KT, Wiencke JK, et al. NAT2 and NQO1 polymorphisms are not associated with adult glioma. Cancer Epidemiol Biomarkers Prev 2001;10:151-2.
10. Saarikoski ST, Reinikainen M, Anttila S, et al. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics 2000;10:183-5.
11. Seow A, Zhao B, Poh WT, et al. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcinogenesis 1999;20:1877-81.
12. Guo W, Lin G, Zha T, Lou K, Ma Q, Shen J. N-acetyltransferase 2 gene polymorphism in a group of senile dementia patients in Shanghai suburb. Acta Pharmacol Sin 2004;25:1112-7.
13. Trizna Z, de Andrade M, Kyritsis AP, et al. Genetic polymorphisms in glutathione S-transferase μ and θ, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol Biomarkers Prev 1998;7:553-5.
14. Olivera M, Martinez C, Molina JA, et al. Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand 2006;113:322-6.
15. Cheng Y-J, Chien Y-C, Hildesheim A, et al. No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2 and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:179-80.
16. El Desoky ES, AbdelSalam YM, Salama RH, et al. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther Drug Monit 2005;27:297-304.
17. Katoh T, Inatomi H, Yang M, Kawamato T, Matsumota T, Bell DA. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 1999;9:401-4.
18. Taylor JA, Umbach DM, Stephens E, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer, evidence of a gene-gene-environment 3-way interaction. Cancer Res 1998;58:3603-10.
19. Bouchardy C, Mitrunen K, Wikman H, et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-8.
20. Habalova V, Salagovic J, Kalina I, Stubna J. A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer. Neoplasma 2005;52:364-8.
21. Bell DA, Stephens EA, Castranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995;55:3537-42.
22. Olshan A, Watson MA, Smith J, Wiessler M, Bell DA. Association of N-acetyltransferase 1 (NAT1) genotype and smoking with risk of head and neck cancers. Proc Am Assoc Cancer Res 1997;8:331.
23. Wikman H, Thiel S, Jager B, et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001;11:157-68.
24. Hou S-M, Fält S, Yang K, et al. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev 2001;10:133-40.
25. De Roos AJ, Rothman N, Inskip PD, et al. Genetic polymorphisms in GSTM1, -P1, -T1 and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 2003;12:14-22.